Quick Takeaways
- PRICE T ROWE ASSOCIATES INC /MD/ filed SCHEDULE 13G for BridgeBio Oncology Therapeutics Inc COMMON STOCK (BBOT).
- Disclosed ownership: 1.1%.
- Date of event: 30 Sep 2025.
PRICE T ROWE ASSOCIATES INC /MD/ - 30 Sep 2025 SCHEDULE 13G Report for BridgeBio Oncology Therapeutics Inc COMMON STOCK (BBOT)
- Filing Manager
- PRICE T ROWE ASSOCIATES INC /MD/
- Reporting Manager
- T. Rowe Price Associates, Inc.
- Symbol
- BBOT
- Shares outstanding
- 80,458,364 shares
- Disclosed Ownership
- 885,042 shares
- Ownership
- 1.1%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Nov 2025, 12:19:23 UTC
- Date of event
- 30 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"PRICE T ROWE ASSOCIATES INC /MD/ disclosed 1.1% ownership in BridgeBio Oncology Therapeutics Inc COMMON STOCK (BBOT) on 30 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Nov 2025, 12:19.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 1.1% | 885,042 | 885,042 | 0 | Ellen York | Vice President |